Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Microglia in Alzheimer’s Disease: A Target for Therapeutic Intervention
Guimei Zhang, Zicheng Wang, Huiling Hu, et al.
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Nour F. Al-Ghraiybah, Junwei Wang, Amer E. Alkhalifa, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10572-10572
Open Access | Times Cited: 91
The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets
Alhamdu Adamu, Shuo Li, Fankai Gao, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 89
Precision drug delivery to the central nervous system using engineered nanoparticles
Jingjing Gao, Ziting Xia, Swetharajan Gunasekar, et al.
Nature Reviews Materials (2024) Vol. 9, Iss. 8, pp. 567-588
Closed Access | Times Cited: 24
Brain-targeted Tet-1 peptide-PLGA nanoparticles for berberine delivery against STZ-induced Alzheimer’s disease in a rat model: Alleviation of hippocampal synaptic dysfunction, Tau pathology, and amyloidogenesis
Samar R. Saleh, Aml Abd-Elmegied, Somaya Aly Madhy, et al.
International Journal of Pharmaceutics (2024) Vol. 658, pp. 124218-124218
Closed Access | Times Cited: 18
Microglial activation states and their implications for Alzheimer's Disease
Zachary Valiukas, Kathy Tangalakis, Vasso Apostolopoulos, et al.
The Journal of Prevention of Alzheimer s Disease (2025) Vol. 12, Iss. 1, pp. 100013-100013
Open Access | Times Cited: 3
Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
Siew Lee Cheong, Jian Kai Tiew, Yi Hang Fong, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1560-1560
Open Access | Times Cited: 45
Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
Daniela Melchiorri, Sara Merlo, Benjamin Micallef, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 25
The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention
Martin Tolar, John A. Hey, Aidan Power, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2727-2727
Open Access | Times Cited: 9
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Taha Basit Ameen, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, et al.
The Egyptian Journal of Neurology Psychiatry and Neurosurgery (2024) Vol. 60, Iss. 1
Open Access | Times Cited: 9
Dynamics of myelin deficits in the 5xFAD mouse model for Alzheimer's disease and the protective role of BDNF
Ioanna Zota, Konstantina Chanoumidou, Ioannis Charalampopoulos, et al.
Glia (2024) Vol. 72, Iss. 4, pp. 809-827
Open Access | Times Cited: 8
Sleep deprivation: A risk factor for the pathogenesis and progression of Alzheimer's disease
Zhengyun Han, Xingmao Yang, Shuiqing Huang
Heliyon (2024) Vol. 10, Iss. 7, pp. e28819-e28819
Open Access | Times Cited: 8
The emerging role of brain neuroinflammatory responses in Alzheimer’s disease
Mandana Amelimojarad, Melika Amelimojarad, Xiaonan Cui
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 8
The neuroinflammatory role of microglia in Alzheimer's disease and their associated therapeutic targets
Melika Amelimojarad, Mandana AmeliMojarad
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 7
Open Access | Times Cited: 8
Modulating Neuroinflammation as a Prospective Therapeutic Target in Alzheimer’s Disease
Eunshil Lee, Yongmin Chang
Cells (2025) Vol. 14, Iss. 3, pp. 168-168
Open Access | Times Cited: 1
Microglial cGAS Deletion Preserves Intercellular Communication and Alleviates Amyloid‐β‐Induced Pathogenesis of Alzheimer's Disease
Sijia He, Xin Li, Namrata Mittra, et al.
Advanced Science (2025)
Open Access | Times Cited: 1
Dysregulated Neurotransmission and the Role of Viruses in Alzheimer’s Disease
Katherine Bovis, Martha Davies-Branch, Philip J. Day
ACS Chemical Neuroscience (2025)
Open Access | Times Cited: 1
The Neuroprotection of Verbascoside in Alzheimer’s Disease Mediated through Mitigation of Neuroinflammation via Blocking NF-κB-p65 Signaling
Shanshan Chen, Honghan Liu, Shimiao Wang, et al.
Nutrients (2022) Vol. 14, Iss. 7, pp. 1417-1417
Open Access | Times Cited: 36
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics
Izabela Lepiarz‐Raba, Ismail Temitayo Gbadamosi, Roberta Florea, et al.
Translational Neurodegeneration (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 21
The immunomodulatory effects of mesenchymal stem cell-derived extracellular vesicles in Alzheimer's disease
Yang Ye, Mingzhu Gao, Wentao Shi, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 7
Developing blood-brain barrier arterial spin labelling as a non-invasive early biomarker of Alzheimer’s disease (DEBBIE-AD): a prospective observational multicohort study protocol
Beatriz Padrela, Amnah Mahroo, Mervin Tee, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e081635-e081635
Open Access | Times Cited: 7
Targeting Microglia in Alzheimer’s Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules
Ziyad M. Althafar
Molecules (2022) Vol. 27, Iss. 13, pp. 4124-4124
Open Access | Times Cited: 25
Monoclonal Antibody Therapy in Alzheimer’s Disease
Monica Neațu, Anca Covaliu, Iulia Ioniță, et al.
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 60-60
Open Access | Times Cited: 13
Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
Ben Boyarko, Sonia Podvin, Barry Greenberg, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12
Comparison of Oleocanthal-Low EVOO and Oleocanthal against Amyloid-β and Related Pathology in a Mouse Model of Alzheimer’s Disease
Ihab M. Abdallah, Kamal M. Al-Shami, Amer E. Alkhalifa, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1249-1249
Open Access | Times Cited: 11
Nanomaterials as Microglia Modulators in the Treatment of Central Nervous System Disorders
Matteo Battaglini, Attilio Marino, Margherita Montorsi, et al.
Advanced Healthcare Materials (2023) Vol. 13, Iss. 12
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top